AstraZeneca’s Imfinzi and Lynparza have been recommended for approval in the European Union, EU, as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been recommended for patients with mismatch repair proficient, pMMR, disease. The Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, based its positive opinion on a prespecified exploratory subgroup analysis by mismatch repair, MMR, status from the DUO-E Phase III trial, which was published in the Journal of Clinical Oncology in October 2023. This analysis showed a reduction in the risk of disease progression or death for pMMR patients in the Lynparza and Imfinzi arm by 43% versus the control arm.1 Results for dMMR patients showed a reduction in the risk of disease progression or death in the Imfinzi arm by 58% versus the control arm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca says Tagrisso with addition of chemo approved in China for NSCLC
- UK Stocks: AstraZeneca’s (AZN) Imfinzi Disappoints in Advanced Lung Cancer Trial
- AstraZeneca’s Imfinzi demonstrated statistically significant improvement
- AstraZeneca’s Tagrisso approved in Japan for 1st-line treatment
- AstraZeneca says ADJUVANT BR.31 Phase III trial did not achieve primary endpoint